GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment.
GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment. Founded in 2020, GenAssist was founded by outstanding scientists and industry experts in July 2020. They are committed to the development of gene editing drugs for a variety of genetic diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 8, 2022 | Series A | — | 1 | AstraZeneca | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
AstraZeneca | Yes | Series A |